This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Prostate Health Market

Thriving Startup Landscape Aids Unbridled Growth of the Prostate Health Market. FMI’s Latest Prostate Health Market Analysis Reveals Promising Trends Across Major Regional Markets

Prostate Health Market By Disease Indication, End User & Region | Forecast 2023 to 2033

Prostate Health Market Outlook

The global Prostate Health Market is anticipated to reach US$ 92.9 billion in 2033, from US$ 38.6 billion in 2023, with a CAGR of 9.2% from 2023 to 2033.

The following factors are projected to drive higher demand for prostate health solutions:

  • The presence of a large target patient population
  • Modern healthcare infrastructure
  • Increased physician awareness
  • Significant rise in the senior population

While BPH (Benign Prostate Hyperplasia) rarely causes symptoms before the age of 40, the disease's risk increases as one get older. Nearly half of the males between the ages of 51 and 60 are affected, while up to 90% of men over 80 are affected. Patients with BPH have received treatment in the form of medicines and surgery.

Attributes

Details

Prostate Health Market CAGR (2023 to 2033)

9.2%

Prostate Health Market (2033)

US$ 92.9 billion

Prostate Health Market Attraction

Awareness about the symptoms of BPH to drive the growth of the prostate health market

Customize this Report

Let us know your requirement to get
100% FREE customization

Increasing Cases of Prostate Cancer Impact Market Growth

According to a recent survey, global prostate cancer is growing at a rate of 7% each year. Factors such as rapidly evolving lifestyles, obesity, and other unhealthy practices have been bolstering the prevalence of diseases such as Benign Prostatic Hyperplasia (BPH). Globally, the geriatric population has been growing tremendously. As age increases, men can be at greater risk of developing prostate-related illnesses such as prostate cancer. In recent times, prostate cancer has become one of the most prevalent cancers among men. This has led to the development of innovations such as the prostate cancer phase III pipeline. This includes prostate-specific membrane antigen targeting as well as the development of kinase and immune checkpoint inhibitors.

Side Effects of Benign Prostatic Hyperplasia Medications Emerge as Concern for Market Growth

Several surgical and drug treatment options are available for Benign Prostatic Hyperplasia (BPH). However, time and again these treatment modalities have been associated with an array of potential side effects. This may include orthostatic hypotension, retrograde ejaculation, rhinitis, dizziness, impotence, and waning libido. This is primarily because Benign Prostatic Hyperplasia medications generally contain alpha-blockers, and 5-ARIs (5-alpha reductase inhibitors). Furthermore, Benign Prostatic Hyperplasia drug interactions have also been observed with neuroactive steroids, which might result in psychological issues.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Prostate Health Market between 2017 to 2022, Compared to Market Outlook between 2023 to 2033

Between 2017 and 2022, the market recorded a CAGR of 11.3%. This was primarily due to the high rate of diagnostics, screening, and tests prevalent during this period. In comparison, the rate of diagnostics and tests determining prostate health has significantly waned at the onset of the forecast period. This is anticipated to impact the CAGR of the market between 2023 and 2033. However, the testing and diagnostics rate could steadily pick up pace towards the middle and end of the forecast period, given the favorable circumstances.

Short Term (2023 to 2026): In the initial phase, the market could experience a slight spur. This can be attributed to the rising prevalence of prostate cancer and increased public knowledge about prostate cancer therapy. This is further fueled by the rising availability of novel medications and prostate cancer therapies. Furthermore, current reports of a high prevalence of BPH, prostate cancer, and prostatitis are rising. There is a strong presence of medical device makers, emerging as critical contributors to market expansion in developed markets.

Mid Term (2026 to 2029): Favorable reimbursement regulations, high disposable incomes, a solid healthcare infrastructure, research funding, and product releases could aid market growth during this phase. Further innovations have led to the adoption of immunotherapy for targeted prostate cancer treatment. This could find wide utility in the mid-term.

Long Term (2029 to 2033): Steady rise in the prevalence of prostate diseases coupled with higher awareness and treatment innovations could consolidate market prospects in the long run. Furthermore, developing markets are expected to emerge as key market stakeholders. This is driven by the consistent growth of healthcare infrastructure in these regions.

During the current forecast period, the market is anticipated to record a CAGR of 9.2%, and attain a valuation of US$ 92.9 billion by 2033.

What are the Primary Drivers of the Prostate Health Market?

The market is being driven ahead by demand for hormone treatment medications, developing therapeutics for prostate cancer, and the increased incidence of prostatitis.

Key Drivers:

  • Prevalence of benign prostatic hyperplasia
  • Increasing obesity
  • Investments, funds, and grants for research in BPH treatment
  • Rising prevalence of prostate cancer
  • Increasing demand for hormone therapy drugs
  • Emerging therapies for prostate cancer
  • Rising incidence of prostatitis

Prostate cancer caused roughly 248,530 new cases and 34,130 deaths in the United States in 2020, according to the American Cancer Society's predictions for 2021. Prostate cancer cases are on the rise, increasing market demand for prostate health supplements.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

What are the Factors Hampering the Growth of the Prostate Health Market?

While both medicines and surgery can treat BPH, both have severe adverse effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other medication groups are routinely used to treat BPH.

Dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis are all common side effects of alpha-blockers. Dizziness and orthostatic hypotension are more common in the elderly, leading to severe complications, such as falls and accidents.

These medications also suppress the manufacture of certain neuroactive hormones, but they may cause depression by modulating the neuroendocrine stress response. Gynecomastia, impotence, decreased libido, and ejaculate volume is among the adverse effects of 5-ARIs.

What are the Opportunities for the Prostate Health Market?

Emerging economies in diverse countries with significant healthcare spending and physician awareness open the market to a variety of opportunities.

Emerging economies (such as China, India, Brazil, and Mexico) are likely to provide considerable growth prospects for market competitors in the next few years.

Key growth Opportunities for the market in developing nations are:

  • A significant target patient population
  • Rising healthcare expenditures
  • Increasing physician awareness
  • Significant growth in the senior population

A substantial patient population for benign prostatic hyperplasia can be found throughout the Asia Pacific region. Particularly in Japan, China, South Korea, and Hong Kong, as the number of geriatric adults is at high risk for these target indications. Hence, prominent and rising prostate health product manufacturers are increasingly focusing on extending their companies across emerging Asia Pacific countries.

What are the Challenges faced by the Prostate Health Market Players?

BPH is frequently misdiagnosed as an untreatable symptom of aging rather than a disorder managed by visiting a urologist.

Due to a lack of awareness about the signs and symptoms of BPH, men can go misdiagnosed, thereby worsening the damage to the prostate. Moreover, undergoing clinical diagnosis for a prostate health check is something that many men still shy away from. Hence, market players have been attempting to increase diagnosis rates through easy at-home diagnosis kits and online appointment facilities.

What are the Key Trends in the Prostate Health Market?

The growing incidence of benign prostatic hyperplasia, obesity, investment opportunities, resources, and cancer are all driving the prostate health market share forward.

Prostate cancer, benign prostate hyperplasia, and prostatitis are the three disease indications that make up the prostate health industry. Prostate cancer is likely to hold the most significant share of the prostate health market in 2023. Hormone therapy is generally thought to be an impactful first-line treatment for prostate cancer.

Following hormonal therapy, cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, prostate health capsules, or chemotherapies are used as alternative therapies. Due to the discovery that cancerous cells build immunity to these medicines immunotherapies are predicted to be widely embraced in coming years. Due to a lack of understanding about the clinical manifestations of prostate health meaning and symptoms, men can go misdiagnosed. This could worsen the symptoms of the disease.

North America has been a pioneer in developing prostate health supplements in the medical sector. The rising target demographic, the high proportion of BPH, prostate cancer, and prostatitis, and the significant influence of medical device makers contribute to the higher growth in the United States.

Supportive regulations, high disposable earnings, solid healthcare infrastructure, and funding for research, are factors propelling the market growth.

Category-wise Insights

Which Disease Indication Segment Holds the significant Share of the Prostate Health Market?

The prostate cancer segment is expected to have a significant market share in the global prostate health market by 2033. Currently, the prostate cancer segment dominates the market and is projected to expand at a CAGR of 8.8% between 2023 and 2033.

The increasing rise in the number of instances of prostate cancer presents enormous prospects for market participants.

The key industry players are focused on research and development to deliver innovative and genuine prostate therapies to the prostate health market. Innovative technologies in screening and diagnostic testing for prostate diseases are projected to drive market expansion. The use of multiparametric MRI (MP-MRI) can significantly improve tumor detection.

Hormone Therapy Segment Shows Promise During Forecast Period Aided by Rise in Prostate Cancer

Due to the rise in the prevalence of prostate cancer, globally, the hormone therapy segment could expand lucratively during this period. Hormone therapy is finding wide adoption for cancer treatment since it has been found effective in reducing relapse of the disease. Several innovations such as antiandrogens as well as luteinizing hormone-releasing hormone antagonists are being introduced to aid the segment’s growth. Since prostate cancer treatment is one of the most revenue-producing segments of the market, hormone therapy follows closely.

Comparative Analysis of Adjacent Markets

Prostate Health Market:

Attributes

Prostate Health Market

CAGR (2023 to 2033)

9.2%

Market Value (2033)

US$ 92.9 billion

Growth Factor


Rising prevalence of prostate cancer as well as BPH to drive adoption.

Opportunity

Increasing awareness among physicians to augment opportunities in the prostate health market.

Key Trends

Growing research funding as well as favorable reimbursement policies remain a key trend.

Prostate Cancer Therapeutics market:

Attributes

Prostate Cancer Therapeutics market

CAGR (2023 to 2033)

8.5%

Market Value (2033)

US$ 27.9 billion

Growth Factor

Low cost of therapeutics over radiotherapy to provide opportunities in developing countries.

Opportunity

Launching of drugs with short market times to provide opportunities.

Key Trends

Multiple products and parallel clinical trials of therapeutics remain key differentiators.

Radiotherapy Market:

Attributes

Radiotherapy Market

CAGR (2023 to 2033)

5.5%

Market Value (2033)

US$ 11.5 billion

Growth Factor

Awareness about radiotherapy procedures to cure cancer is governing the demand.

Opportunity

Market players can focus on reducing the expense of radiotherapy to penetrate developing economies.

Key Trends

Advancements and innovation in radiotherapy to boost growth.

Regional Outlook

North America Leads Prostate Health Market; Thrust from Key Regional Drivers

North America dominated the prostate health market in 2023, and the region is predicted to rise at a 7.6% CAGR by 2033. North America has been a leader in developing prostate health therapies in the medical field.

There is a rising target population, a high incidence of BPH (prostate problems in older men), prostate cancer, and prostatitis, and the strong presence of medical device manufacturers in the United States (a significant contributor to the North American prostate health market).

The United States prostate health market is anticipated to capture a CAGR of 9.0% to attain a valuation of US$ 32.9 billion by 2033.

Factors favoring the North American market are:

  • Favorable reimbursement regulation
  • High disposable incomes
  • A competent healthcare infrastructure
  • Research funding for prostate vitamins
  • Product releases like prostate support

Europe Follows Close Pursuit as the Second Leading Market: Bolstered by Strong Healthcare Infrastructure

In the current decade, Europe has emerged as one of the global leaders in providing prostate cancer therapies. Much like North America the region has also been experiencing a surge in prostate cancer and related ailments. Hence, the production and sales of targeted prostate treatment drugs such as Zytiga and Xtandi have steadily grown. Further, the region has a large geriatric population necessitating focused health services. Hence, the United Kingdom is projected to be a lucrative market for prostate health products.

During the forecast period, the United Kingdom's prostate health market is anticipated to record a CAGR of 8.2% and expand to US$ 3.9 billion by 2033.

Regions North America
Countries United States
CAGR 9.0%
Market Value (2033) US$ 32.9 billion
Regions Europe
Countries United Kingdom
CAGR 8.2%
Market Value (2033) US$ 3.9 billion
Regions Asia Pacific
Countries China, South Korea
CAGR 8.6%, 7.2%
Market Value (2033) US$ 6.7 billion, US$ 3.3 billion

Key Players Steer Market Growth with Research & Innovations

The introduction of the new and best prostate supplement is likely to substantially impact the prostate health market. A detailed understanding of disease pathogenesis is likely to aid in the development of new prostate cancer therapeutics.

These key players and academics in the prostate health market assess challenges and look for chances to improve prostate cancer research and development. Novel techniques to treat/improve the disease status focus on prostate cancer therapies in the prostate health market.

Recent Developments in the Prostate Health Market:

Company Butterfly Medical
Details

Butterfly Medical is an Israeli medical device manufacturer of innovative implantable devices. These find wide application in the treatment of Benign Prostatic Hyperplasia (BPH).The company is known for developing alternatives to traditional BPH treatments.

Recent Developments Butterfly Medical, raised US$ 7 million in Series B financing in October 2020 to develop an anatomically designed nitinol implant positioned in the prostatic urethra to alleviate BPH symptoms.
Company Zenflow
Details Zenflow is a medical device company based in California. The company aims to fill the market gap for less invasive treatments related to BPH.
Recent Developments Zenflow announced a US$ 31.4 million Series A funding round in February 2018 to continue its minimally invasive method to treat BPH. Its solution is a device that props open the urethra, effectively curing BPH symptoms without surgery or medicine.
Recent Developments Butterfly Medical, raised US$ 7 million in Series B financing in October 2020 to develop an anatomically designed nitinol implant positioned in the prostatic urethra to alleviate BPH symptoms.
Company ProArc
Details ProArc is an Israeli company developing minimally invasive solutions in urology. The company aims to radically alter the treatment landscape for BPH.
Recent Developments ProArc Medical was awarded a US$ 2.2 million grant from the Horizon 2020 program as a part of the European Innovation Council pilot in July 2019. The two-year award is likely to fund the research and development of ProArc's ClearRing BPH implant, as well as its commercialization.

Leading Start-ups to Lookout For

Start-up Company Bastion Health
Country United States
Description To alleviate inhibitions surrounding prostate health, the startup has come up with several innovations. This includes home self-evaluation kits and easy telephone appointments.
Start-up Company Nucleai
Country United States
Description Nucleai is known for developing software that amalgamates computer vision with machine-learning algorithms to detect prostate cancer. This can aid in reducing diagnosis errors and diagnostics time. The software deeply analyses patients’ medical records as well as genomics data for conclusive inferences.

Key Players

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca
  • Bayer AG
  • Dendreon Pharmaceuticals LLC
  • Endo Pharmaceuticals, Inc.
  • Ipsen Pharma
  • Johnson & Johnson Services
  • Pfizer, Inc.
  • Sanofi

Key Segments

By Disease Indication:

  • Prostate Cancer
  • Benign Prostate Hyperplasia
  • Prostatitis

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Frequently Asked Questions

The global prostate health market is expected to register a CAGR of 9.2% from 2023 to 2033.

The size of the prostate health market is anticipated to be valued at US$ 92.9 billion by 2033.

The size of the prostate health market is projected to be US$ 38.6 billion in 2023.

North America region dominates the global prostate health market.

Currently, prostate cancer is the top segment by disease indication category.

Table of Content

1. Executive Summary | Prostate Health Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Investment Feasibility Matrix

    3.6. PESTLE and Porter’s Analysis

    3.7. Regulatory Landscape

        3.7.1. By Key Regions

        3.7.2. By Key Countries

    3.8. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033

        5.3.1. Prostate Cancer

        5.3.2. Benign Prostate Hyperplasia

        5.3.3. Prostatitis

    5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    6.1. Introduction

    6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        6.3.1. North America

        6.3.2. Latin America

        6.3.3. Europe

        6.3.4. Asia Pacific

        6.3.5. Middle East and Africa

    6.4. Market Attractiveness Analysis By Region

7. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        7.2.1. By Country

            7.2.1.1. The USA

            7.2.1.2. Canada

        7.2.2. By Disease Indication

    7.3. Market Attractiveness Analysis

        7.3.1. By Country

        7.3.2. By Disease Indication

    7.4. Key Takeaways

8. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. Brazil

            8.2.1.2. Mexico

            8.2.1.3. Rest of Latin America

        8.2.2. By Disease Indication

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Disease Indication

    8.4. Key Takeaways

9. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Germany

            9.2.1.2. United Kingdom(U.K)

            9.2.1.3. France

            9.2.1.4. Spain

            9.2.1.5. Italy

            9.2.1.6. Russia

            9.2.1.7. Rest of Europe

        9.2.2. By Disease Indication

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease Indication

    9.4. Key Takeaways

10. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. China

            10.2.1.2. Japan

            10.2.1.3. India

            10.2.1.4. South Korea

            10.2.1.5. Australia

            10.2.1.6. Rest of APAC

        10.2.2. By Disease Indication

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Indication

    10.4. Key Takeaways

11. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. South Africa

            11.2.1.2. Saudi Arabia

            11.2.1.3. UAE

            11.2.1.4. Israel

            11.2.1.5. Rest of MEA

        11.2.2. By Disease Indication

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Indication

    11.4. Key Takeaways

12. Key Countries Market Analysis

    12.1. USA

        12.1.1. Pricing Analysis

        12.1.2. Market Share Analysis, 2022

            12.1.2.1. By Disease Indication

    12.2. Canada

        12.2.1. Pricing Analysis

        12.2.2. Market Share Analysis, 2022

            12.2.2.1. By Disease Indication

    12.3. Brazil

        12.3.1. Pricing Analysis

        12.3.2. Market Share Analysis, 2022

            12.3.2.1. By Disease Indication

    12.4. Mexico

        12.4.1. Pricing Analysis

        12.4.2. Market Share Analysis, 2022

            12.4.2.1. By Disease Indication

    12.5. Germany

        12.5.1. Pricing Analysis

        12.5.2. Market Share Analysis, 2022

            12.5.2.1. By Disease Indication

    12.6. UK

        12.6.1. Pricing Analysis

        12.6.2. Market Share Analysis, 2022

            12.6.2.1. By Disease Indication

    12.7. France

        12.7.1. Pricing Analysis

        12.7.2. Market Share Analysis, 2022

            12.7.2.1. By Disease Indication

    12.8. Spain

        12.8.1. Pricing Analysis

        12.8.2. Market Share Analysis, 2022

            12.8.2.1. By Disease Indication

    12.9. Italy

        12.9.1. Pricing Analysis

        12.9.2. Market Share Analysis, 2022

            12.9.2.1. By Disease Indication

    12.10. Russia

        12.10.1. Pricing Analysis

        12.10.2. Market Share Analysis, 2022

            12.10.2.1. By Disease Indication

    12.11. China

        12.11.1. Pricing Analysis

        12.11.2. Market Share Analysis, 2022

            12.11.2.1. By Disease Indication

    12.12. Japan

        12.12.1. Pricing Analysis

        12.12.2. Market Share Analysis, 2022

            12.12.2.1. By Disease Indication

    12.13. India

        12.13.1. Pricing Analysis

        12.13.2. Market Share Analysis, 2022

            12.13.2.1. By Disease Indication

    12.14. South Korea

        12.14.1. Pricing Analysis

        12.14.2. Market Share Analysis, 2022

            12.14.2.1. By Disease Indication

    12.15. Australia

        12.15.1. Pricing Analysis

        12.15.2. Market Share Analysis, 2022

            12.15.2.1. By Disease Indication

    12.16. South Africa

        12.16.1. Pricing Analysis

        12.16.2. Market Share Analysis, 2022

            12.16.2.1. By Disease Indication

    12.17. Saudi Arabia

        12.17.1. Pricing Analysis

        12.17.2. Market Share Analysis, 2022

            12.17.2.1. By Disease Indication

    12.18. UAE

        12.18.1. Pricing Analysis

        12.18.2. Market Share Analysis, 2022

            12.18.2.1. By Disease Indication

    12.19. Israel

        12.19.1. Pricing Analysis

        12.19.2. Market Share Analysis, 2022

            12.19.2.1. By Disease Indication

13. Market Structure Analysis

    13.1. Competition Dashboard

    13.2. Competition Benchmarking

    13.3. Market Share Analysis of Top Players

        13.3.1. By Regional

        13.3.2. By Disease Indication

14. Competition Analysis

    14.1. Competition Deep Dive

        14.1.1. Eli Lilly and Company

            14.1.1.1. Overview

            14.1.1.2. Product Portfolio

            14.1.1.3. Profitability by Market Segments

            14.1.1.4. Sales Footprint

            14.1.1.5. Strategy Overview

                14.1.1.5.1. Marketing Strategy

        14.1.2. Pfizer Inc.

            14.1.2.1. Overview

            14.1.2.2. Product Portfolio

            14.1.2.3. Profitability by Market Segments

            14.1.2.4. Sales Footprint

            14.1.2.5. Strategy Overview

                14.1.2.5.1. Marketing Strategy

        14.1.3. Merck & Co., Inc.

            14.1.3.1. Overview

            14.1.3.2. Product Portfolio

            14.1.3.3. Profitability by Market Segments

            14.1.3.4. Sales Footprint

            14.1.3.5. Strategy Overview

                14.1.3.5.1. Marketing Strategy

        14.1.4. GlaxoSmithKline plc.

            14.1.4.1. Overview

            14.1.4.2. Product Portfolio

            14.1.4.3. Profitability by Market Segments

            14.1.4.4. Sales Footprint

            14.1.4.5. Strategy Overview

                14.1.4.5.1. Marketing Strategy

        14.1.5. Abbott

            14.1.5.1. Overview

            14.1.5.2. Product Portfolio

            14.1.5.3. Profitability by Market Segments

            14.1.5.4. Sales Footprint

            14.1.5.5. Strategy Overview

                14.1.5.5.1. Marketing Strategy

        14.1.6. Astellas Pharma Inc.

            14.1.6.1. Overview

            14.1.6.2. Product Portfolio

            14.1.6.3. Profitability by Market Segments

            14.1.6.4. Sales Footprint

            14.1.6.5. Strategy Overview

                14.1.6.5.1. Marketing Strategy

        14.1.7. Johnson & Johnson Services Inc.

            14.1.7.1. Overview

            14.1.7.2. Product Portfolio

            14.1.7.3. Profitability by Market Segments

            14.1.7.4. Sales Footprint

            14.1.7.5. Strategy Overview

                14.1.7.5.1. Marketing Strategy

        14.1.8. AbbVie

            14.1.8.1. Overview

            14.1.8.2. Product Portfolio

            14.1.8.3. Profitability by Market Segments

            14.1.8.4. Sales Footprint

            14.1.8.5. Strategy Overview

                14.1.8.5.1. Marketing Strategy

        14.1.9. Sanofi

            14.1.9.1. Overview

            14.1.9.2. Product Portfolio

            14.1.9.3. Profitability by Market Segments

            14.1.9.4. Sales Footprint

            14.1.9.5. Strategy Overview

                14.1.9.5.1. Marketing Strategy

        14.1.10. Siemens Healthcare AG

            14.1.10.1. Overview

            14.1.10.2. Product Portfolio

            14.1.10.3. Profitability by Market Segments

            14.1.10.4. Sales Footprint

            14.1.10.5. Strategy Overview

                14.1.10.5.1. Marketing Strategy

15. Assumptions & Acronyms Used

16. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 3: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 5: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 6: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 7: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 8: Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 9: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 10: Asia Pacific Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Table 11: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2017 to 2033

Table 12: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 3: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033

Figure 4: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 5: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 9: Global Market Attractiveness by Disease Indication, 2023 to 2033

Figure 10: Global Market Attractiveness by Region, 2023 to 2033

Figure 11: North America Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 12: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 13: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 14: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 15: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 16: North America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 17: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 18: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 19: North America Market Attractiveness by Disease Indication, 2023 to 2033

Figure 20: North America Market Attractiveness by Country, 2023 to 2033

Figure 21: Latin America Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 22: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 23: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 24: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 25: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 26: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 27: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 28: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 29: Latin America Market Attractiveness by Disease Indication, 2023 to 2033

Figure 30: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 31: Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 32: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 33: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 34: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 35: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 36: Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 37: Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 38: Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 39: Europe Market Attractiveness by Disease Indication, 2023 to 2033

Figure 40: Europe Market Attractiveness by Country, 2023 to 2033

Figure 41: Asia Pacific Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 42: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 43: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 44: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 45: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 46: Asia Pacific Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 47: Asia Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 48: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 49: Asia Pacific Market Attractiveness by Disease Indication, 2023 to 2033

Figure 50: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 51: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 52: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 53: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2017 to 2033

Figure 54: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 55: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 56: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033

Figure 57: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 58: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 59: Middle East and Africa Market Attractiveness by Disease Indication, 2023 to 2033

Figure 60: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Prostate Health Market

Published : February 2022

Healthcare

Healthcare Regulatory Affairs Outsourcing Market

Published : December 2021

Healthcare

Hormone Sensitive Prostate Cancer Market

Published : April 2016

Google translate

Prostate Health Market